Morphine dependency blocked by single genetic change

Morphine’s serious side effect as a pain killer – its potential to create dependency – has been almost completely eliminated in research with mice by genetically modifying a single trait on the surface of neurons. The study scientists think a drug can be developed to similarly block dependency.

The research was published online January 17 by “Current Biology” and appears in the journal’s January 23 print edition. The scientists were led by Jennifer Whistler, PhD, an investigator in the UCSF-affiliated Ernest Gallo Clinic and Research Center, and associate professor of neurology at UCSF.

Millions of people in the U.S. are given the opiate drug morphine for extreme pain caused by cancer, surgery, nerve damage and other conditions. It remains the pain killer of choice for many types of short-term pain, such as surgery, according to Whistler, but it is less useful for the treatment of chronic pain because its effectiveness decreases with continued use in a process called tolerance. As a consequence, an increasingly larger dose is required to treat the pain, thereby increasing the chance of addiction.

The body’s natural pain killers, such as endorphins, ease pain by first binding to receptors on the surface of neurons. The receptors cycle on and off “like a light switch,” Whistler says, regulating the intake of endorphin. This crucial control is absent when the neurons encounter morphine. The researchers’ strategy in their study was to try to trick neurons into responding to morphine in the more regulated way.

Strong evidence suggests that the natural on-off cycling occurs because the endorphin receptor withdraws from the cell surface, toward the cell’s interior, Whistler says. The migration from the cell surface is called endocytosis.

When the neuron receptors encounter morphine the light switch is broken, and the nervous system responds by becoming more tolerant of the drug, making the recipient more dependent on the drug.

To demonstrate their hunch that morphine’s unwanted effects were caused by the failure of its receptor to withdraw from the cell surface, the researchers genetically engineered mice with a single difference from normal mice: Receptors that encounter morphine in these mice can undergo endocytosis, as they normally do in the presence of endorphins. The researchers showed that with this single change, morphine remained an excellent pain killer without inducing tolerance and dependence.

“As more pain medications are being removed from the market, new strategies to overcome chronic pain become crucial,” Whistler says. “If new opiate drugs can be developed with morphine’s pain killing properties but also with the ability to promote endocytosis, they could be less likely to cause the serious side effects of tolerance and dependence.”

The research is the first direct demonstration that this single cellular change can block the body’s tendency to become tolerant of the drug, she points out.

Several strategies are now being tested to counter morphine addiction, Whistler says. These include development of morphine derivatives such as oxycontin, that are delivered in a time released manner or only once they have been processed in the digestive system. Other approaches seek to develop morphine derivatives that target only certain opioid receptors but not others.

“The most promising aspect of these other approaches is that they have the potential to prevent or delay dependence and addiction to morphine, but few of them address the development of tolerance,” Whistler said.

Source: University of California - San Francisco

Related stories:

Study finds addictive drugs easily ordered online
(AP) -- More than three-quarters of Web sites that offer highly addictive medications do not require a prescription, according to a study released Wednesday.
How best to treat chronic pain? The jury is still out
How best to alleviate chronic pain, a leading cause of disability and employee absenteeism, continues to perplex both patients and their doctors.
FDA OKs Relistor for opioid patients
The U.S. Food and Drug Administration has approved Relistor (methylnaltrexone bromide) to help restore bowel function in patients receiving opioids.
Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs
Help is on the way for patients who have undergone back surgery but who continue to suffer from chronic pain in their backs and legs, thanks to a novel technology pioneered by two Chicago-area pain management specialists.
Chronic pain should be considered a disease
The concept that chronic pain is a disease in its own right is leading to new specific treatments aimed at physical, psychological, and environmental components of this major disease, including genetic predisposition, according to a world renowned pain medicine expert.
Researchers find relief for chronic pain
Researchers in the Department of Medicine and Department of Neurosciences at Mount Sinai School of Medicine have discovered that chronic pain can be successfully treated with novel targeted gene therapy. In an effort to find a more effective treatment for chronic pain, researchers at Mount Sinai developed a gene therapy technique that simulates the pain-killing effect of opiate drugs.
The more we get, the more we need: Study shows how to prevent morphine 'tolerance'
Tolerance to the pain-relieving effects of morphine – which builds rapidly with prolonged use – can be prevented by blocking a key substance that’s formed when the drug is taken, researchers at the Saint Louis University of Medicine have discovered.
Acupuncture Reduces Pain, Need for Opioids after Surgery
Using acupuncture before and during surgery significantly reduces the level of pain and the amount of potent painkillers needed by patients after the surgery is over, according to Duke University Medical Center anesthesiologists who combined data from 15 small randomized acupuncture clinical trials.

News discussion:

Medicine & Health news